Filing Flows › BridgeBio Pharma (BBIO) › Q3 2026 › vs Q3 2025
BridgeBio Pharma (BBIO) Q3 2026 vs Q3 2025 (year over year)
BridgeBio Pharma's revenue rose $232M (+193%) from $121M in Q3 2025 to $353M in Q3 2026. The biggest changes: Net product revenue +$145M (+134%); License and services revenue +$71.0M (+854%); Royalty revenue +$16.2M (+379%).
BridgeBio Pharma, Q3 2026: revenue $353M (+193% year over year), operating margin -3.3%, net loss $60.5M, operating cash flow −$44.2M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Net product revenue | $253M | $108M | $145M | +134% |
| License and services revenue | $79.3M | $8.3M | $71.0M | +854% |
| Royalty revenue | $20.5M | $4.3M | $16.2M | +379% |
| Revenue | $353M | $121M | $232M | +193% |
| Net loss | $60.5M | $185M | −$124M | -67% |
| Costs & expenses | $414M | $307M | $106M | +35% |
| Operating costs | $365M | $266M | $98.9M | +37% |
| Interest & other, net | $47.6M | $41.3M | $6.3M | +15% |
| Income tax | $1.2M | −$1.5M | $2.8M | — |
| Cost of revenue | $20.4M | $6.6M | $13.9M | +212% |
| Research & development | $144M | $113M | $30.6M | +27% |
| SG&A | $201M | $138M | $63.2M | +46% |
| Operating cash sources | $85.1M | $146M | −$61.1M | -42% |
| Depreciation & amortization | $1.1M | $1.4M | −$329K | -24% |
| Share-based compensation | $39.9M | $35.3M | $4.6M | +13% |
| Cash used in operations | $44.2M | $110M | −$65.4M | -60% |
| Net loss absorbed | $60.5M | $185M | −$124M | -67% |
| Working capital & other | $24.6M | −$38.7M | $63.3M | — |
Questions
How much did BridgeBio Pharma's revenue grow year over year in Q3 2026?
BridgeBio Pharma's revenue rose $232M (+193%) from $121M in Q3 2025 to $353M in Q3 2026.
What drove BridgeBio Pharma's revenue change in Q3 2026?
Net product revenue +$145M (+134%); License and services revenue +$71.0M (+854%); Royalty revenue +$16.2M (+379%).